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Finding new therapies to assist in the treatment of cancer is a major challenge of clinical research. Small molecules that inhibit different
molecular targets at the different levels of the MAPK pathway have been developed. Several MEK inhibitors have been examined in early-phase
clinical trials and the current state of clinical results using these therapies is presented here.
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Proliferation, differentiation, and cell death are coordinated
processes that help maintain homeostasis among the diverse cell
types in higher organisms. Growth factors play a key role in the
control of these processes and exert this function by triggering
signal transduction cascades upon binding to their cognate
membrane receptors. Given the importance of homeostasis and
the multiple components involved, it is not surprising that any
component of these regulatory cascades, from the growth factor
to the final effector, may become unregulated and contribute to
transformation and tumorigenesis.
Through years of study, the Ras-mitogen activated protein
kinase (MAPK) pathway has emerged as the central piece of a
signaling network regulating cell growth and survival. The
MAPK pathway acts by transferring growth-promoting signals
from the cell surface or cytoplasm to the nucleus through a
sequential protein kinase cascade that regulates a wide array of
substrates, including transcription factors, cytoskeletal ele-
ments, and other protein kinases. These signals have been
demonstrated to contribute to a myriad of cellular functions,
including cell division, proliferation, growth, differentiation,
movement and cell death.
The MAPK pathway has been widely observed to be
dysregulated in various humanmalignancies. Constitutive activa-⁎ Corresponding author.
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to malignant transformation of mammalian cells, and has been
associated with an aggressive neoplastic phenotype, including
uncontrolled cell proliferation and resistance to apoptosis. A
wide spectrum of inhibitors against the components of this
pathway have been sought after, discovered and investigated,
both in vitro and in vivo, and they have demonstrated anticancer
effects by suppressing tumor growth, limiting cancer invasion
and/or inducing apoptosis of cancer cells.
2. RAS and BRAF mutations in human cancers
Constitutive activation of the MAPK pathway may con-
tribute to cancer cell resistance to chemotherapy in many human
malignancies, including pancreatic, colon, lung, ovary, breast,
thyroid and kidney cancers [1–3]. Thus, identifying mutations
in critical genes of the MAPK pathway which result in abnormal
activity has been a high priority of researchers.
RAS proteins were some of the first proteins to be identified
as having a role in the regulation of cell growth [4]. Human
tumors frequently express RAS proteins that are constitutively
activated by point mutations; approximately 20% of all tumors
have an activating mutation in at least one RAS gene [5].
Aberrant activation of RAS proteins contributes significantly to
the malignant phenotype by deregulating tumor cell growth in
the tumor, apoptosis, invasiveness, and angiogenesis [6]. In
order to be biologically active, RAS proteins require post-
translational modification. Enzymes performing this modifica-
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the testing of several therapeutic agents [7]. Unfortunately,
studies of farnesyltransferase inhibitors have been disappointing
to date [8]. Therefore, therapies designed to specifically target
downstream signaling pathways controlled by RAS, rather than
RAS itself, have increasingly become the subject of testing.
BRAF mutations occur at a high frequency in melanomas,
and to a lesser extent in thyroid, ovarian, colon, lung, and other
tumor types [9–13]. Most of these BRAF mutations are located
in the kinase domain, leading to elevated kinase activity and
transforming activity [13]. The identification of BRAF as an
oncogene led to renewed interest in the discovery and
development of pharmacologic inhibitors to target BRAF
proteins. One of these, BAY 43-9006 (Sorafenib), was initially
developed as a targeted specific BRAF inhibitor and entered
into Phase I and Phase II testing, but was later found to inhibit
VEGF and PDGF receptors on blood vessel cells [14]. While
several pharmaceutical companies are now developing agents
that specifically target BRAF, clinical trials of these inhibitors
have yet to be performed.
Mutations in RAS and BRAF typically demonstrate mutual
exclusivity in tumors; therefore, either mutation might exert its
oncogenic activity through common downstream proteins such
as the mitogen-activated protein kinase kinase (MEK) and the
extracellular signal-related kinase (ERK), and these enzymes
may be better exploited as drug targets. Solit et al. examined
the effects of BRAF mutations on the activity of the
downstream MEK and ERK kinase cascade [15]. The authors
used small-molecule MEK inhibitors in cells with RAS or
BRAF mutations and found that tumors with BRAF mutations
demonstrated enhanced sensitivity to MEK inhibition when
compared with wild-type cells and cells harboring various RAS
mutations. In addition, following treatment with MEK
inhibitors, growth of tumors in BRAF-mutant xenografts was
completely suppressed whereas RAS-mutant tumors were only
partially inhibited. The finding that tumors containing muta-
tions in BRAF are much more dependent on MEK inhibition
than tumors with mutant RAS has implications for drug
development; it is possible that MEK inhibitors have a
selectivity that could potentially be exploited in the treatment
of BRAF-mutation-dependent cancers.
3. MEK inhibitors
Numerous small molecules that inhibit different molecular
targets, at the different levels of the MAPK pathway, have beenTable 1
Clinical trials of MEK inhibitors
Agent Phase Adverse events Clinica
CI-1040
(PD 184352)
I Diarrhea, nausea, asthenia, and rash Sixty-s
PR. Ni
II Diarrhea, nausea, asthenia, and rash No res
PD 0325901 I Rash, diarrhea, visual disturbance, nausea,
edema, pruritis, anemia, and dyspepsia
Twenty
achieve
ARRY-142886
(AZD6244)
I Rash, diarrhea, nausea, fatigue, peripheral edema,
vomiting, change in taste, and blurred vision
Of 57 pdiscovered [16–20]. Some of these have recently entered
human clinical trials to evaluate their safety, toxicities, and to
assess their activity against various cancer types. This targeted
therapy includes the clinical development of drugs that
specifically inhibit MEK. MEK inhibitors represent the first
selective inhibitors of MAPK pathway activation to enter the
clinic. Several MEK inhibitors have been examined in early-
phase clinical trials and the current state of clinical results using
these therapies is presented here (Table 1).
3.1. PD098059 and UO126
The first MEK inhibitor to be disclosed was PD 098059
[2-(2′-amino-3′-methoxyphenyl)-oxanaphthalen-4-one] [17]. It
has been mostly used in cell systems to study MEK inhibition in
order to further delineate the role of the MAPK pathway in
carcinogenesis [17,21–25]. Similarly, U0126, a second MEK
inhibitor with more potency than PD 098059, has been mostly
used as an in vitro laboratory reagent [16,26,27]. These particular
inhibitors are non-competitive with ATP and act on the MAPK
cascade by preventing the activation of MEK and not by
inhibiting MEK activity directly [28]. In an in vitro assay, none
of these compounds significantly inhibited the activity of a large
panel of protein kinases, including ERK1, c-Jun N-terminal
kinase (JNK) 1, and p38 MAP kinases [28]. Unfortunately,
PD98059 has not been shown to be sufficiently soluble nor
sufficiently bioavailable to be conducive to clinical testing
(Sebolt-Leopold, J.S., personal communication). Due to this
limitation, PD98059 only has activity in vitro. The only in vivo
activity reported for U0126 was by intraperitoneal administra-
tion [29]. Based on the lack of reported oral activity for U0126, it
presumably suffers from the same limitations as PD98059.
3.2. CI-1040 (PD184352)
Due to the attractive anticancer potential of MEK inhibitors,
continued efforts have been invested in their discovery and
development. CI-1040 (PD 184352) was the first MEK inhibitor
reported to inhibit tumor growth in vivo [18,19]. In mice with
colon carcinomas of both mouse and human origin, tumor
growth was inhibited by as much as 80% after treatment with
CI-1040 [18]. Reported toxicity was minimal, and efficacy
correlated with a reduction in the levels of phosphorylated ERK
(pERK) in excised tumors.
Based on such preclinical activity, CI-1040 became the first
MEK inhibitor moved into a clinical trial [30]. This initial phasel activity
ix patients evaluable for response. One patient with pancreatic cancer achieved
neteen additional patients with a variety of solid tumors achieved SD.
ponse documented. Eight patients with a variety of solid tumors achieved SD.
-seven patients evaluable for response. Two patients with melanoma
d PR. Eight additional patients with a variety of solid tumors achieved SD.
atients, 39 completed 1 cycle, 19 achieved SD, 9 of which were > 5 months.
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with the purpose of defining the toxicity, pharmacokinetics,
pharmacodynamics, maximum tolerated dose (MTD) and initial
clinical activity of CI-1040. Similar to PD 098059 and UO126,
the mechanism of MEK 1/2 inhibition is non-competitive with
respect to ATP, as the compound binds to a unique allosteric site,
thus ensuring its strict specificity against its target.
As the first ever human trial with this compound, extensive
efforts were made to determine an acceptable treatment
schedule. CI-1040 was initially administered once daily from
100 mg/day all the way up to 1600 mg/day. To achieve a
maximal pharmacokinetic (AUC) exposure within the MTD,
multiple daily dosing of CI-1040, including 800 mg bid and tid,
were also tested. In addition, the effect of food intake on drug
absorption was also studied in this trial. In order to assess MEK
inhibition, levels of pERK were evaluated from both peripheral
blood mononuclear cells (PBMCs) and through biopsies of
several patients with accessible tumors.
A total of 77 patients received at least one dose of CI-1040
and were assessable for toxicity. The most frequent tumors
types enrolled included colorectal (n=25), non-small-cell lung
(n=10), pancreatic (n=6), melanoma (n=6), and kidney (n=5).
The most common toxicities were generally grade 1 or 2 in
severity and included diarrhea, asthenia, rash, nausea, and
vomiting. There were no drug-related grade 4 events. Admin-
istration with food increased oral absorption of CI-1040 by
three- to five-fold, and continuous dosing of 800 mg bid with
food was determined to be safe for phase II testing. Increasing
the dosing frequency from once daily to bid resulted in a
substantial increase in daily exposure (AUC) at steady-state,
with the tid regimen providing minimal increased exposure over
bid at steady state. Sixty-six patients were assessable for
response. One patient with pancreatic cancer achieved a partial
response (PR) lasting 12 months, and 19 additional patients,
with a variety of solid tumors, achieved stable disease (SD)
lasting a median of 5.5 months (range, 4 to 17 months).
Phosphorylated ERK levels were measured in tumor samples by
quantitative immunohistochemistry and were found to be inhi-
bited by an average of 71% (range, 46% to 100%), indicating
promising on-target activity.
On the basis of these encouraging phase I results, a phase II,
multicenter, parallel arm study was carried out in patients with
advanced breast cancer, colon cancer, non-small-cell lung
cancer (NSCLC), and pancreatic cancer [31]. Due to the poor
metabolic stability and bioavailabilty of the drug as demon-
strated by the Phase I study, patients received oral CI-1040
continuously at a high dose of 800 mg bid. Expression of
pERK, pAkt, and Ki-67 were assessed in archived tumor
specimens by quantitative immunohistochemistry.
A total of 67 patients with breast (n=14), colon (n=20),
NSCLC (n=18), and pancreatic (n=15) cancer received at least
one dose of CI-1040. Treatment was well tolerated, with 81% of
patients experiencing toxicities of grade 2 or less severity. Only
13 patients (19%) experienced toxicities of grade 3 severity.
Among the most common toxicities (≥10% of patients)
observed in this trial, in descending order of incidence, were
diarrhea, nausea, asthenia, rash, edema, vomiting, abdominalpain, anorexia and facial edema. These toxicities were generally
mild or moderate in severity. A serial measurement of left
ventricular ejection fraction (LEVF) after three cycles of
treatment was performed in 28 patients. Seven of them
experienced asymptomatic decreases of LVEF ≥10%. An
additional patient developed a symptomatic decrease of LVEF
from 60% at baseline to 15% at a time when the patient had
complications of sepsis in the intensive-care setting. At this
time, it remains unclear whether the decrease of LVEF observed
in some of the patients was a result of MEK inhibition from
CI-1040 therapy or was due to cardiac deconditioning resulting
from their progressive deteriorating nutritional status and
advanced malignancies.
In contrast to the phase I study, no complete or partial
responses were observed. A mild association (P< .055) between
baseline pERK expression in archived tumor specimens and SD
was observed. Stable disease, lasting a median of 4.4 months
(range, 4 to 18 months), was confirmed in eight patients (one
breast, two colon, two pancreas, and three NSCLC patients).
While CI-1040 was generally well tolerated, its antitumor
activity, metabolic stability, and bioavailability were considered
insufficient to warrant further development in the four tumor
types tested. Development of CI-1040 was terminated in favor
of developing a more potent and biopharmaceutically superior
compound.
3.3. PD 0325901
A second-generation oral MEK inhibitor, compound PD
0325901, was subsequently developed. Relatively minor
changes distinguish the chemical structure of PD 0325901
from that of CI-1040. The cyclopropylmethoxy group of
CI-1040 was replaced with a (R)-dihydroxy-propoxy group
and the 2-chloro substituent of CI-1040 was replaced with a 2-
flouro group on the second aromatic ring (Fig. 1). Nevertheless,
these minor structural changes imparted significant increases in
potency with PD 0325901. In pre-clinical testing, potency for
target inhibition by PD 0325901 (pERK suppression) was
increased >90-fold relative to CI-1040, and pre-clinical efficacy
(the dose necessary to achieve a 70% complete response (CR) in
the murine C26 cellular assay) was increased >30-fold. This
increase in potency, together with improved bioavailability,
resulted in a predicted dose in human subjects of approximately
15 mg/day compared to the CI-1040 dose of 1600 mg/day, a
greater than 2 log difference. PD 0325901 has an IC50 value of
1 nM against MEK1/2 and has been demonstrated to inhibit
tumor growth in six out of seven tumor xenograft models tested
[19]. These preclinical findings of significantly improved
pharmacologic and pharmaceutical properties of PD 0325901
were determined to hold promise for the use of the compound as
a therapeutic agent.
The first-in-human trial of PD 0325901 employed an open-
label, dose-escalating design [32,33]. Several biopsies were a
requirement of this study. Patients with any of four tumor types,
including breast, colon, nonsmall cell lung cancer (NSCLC), or
melanoma, were considered for enrollment. At the time of initial
reporting, two-thirds of the patients enrolled in this study had
Fig. 1. Comparison of chemical structures and activity of PD 0325901 andCI-1040. The cyclopropylmethoxy group onCI-1040 has been substituted for a (R)-dihidroxy-
propoxy group and the 2-chloro substituent on CI-1040 has been substituted for a 2-fluoro group on the second aromatic ring. * Effective concentration (EC90) in murine
C26 cellular assay achieving 90% pERK suppression. † Dose necessary to achieve 70% CR in C26 model. ‡ 800 mg BID for CI-1040; Predicted dose for PD 325901.
Fig. 2. Chemical structure of the MEK inhibitor ARRY-142886 (AZD6244).
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for biopsy in these patients. Patients with breast, lung and colon
cancers accounted for 17%, 12% and 5% of enrollment,
respectively.
Initial patients received a 21-day course of oral PD
0325901 (qd or bid) every 4 weeks. Eventually, the regimen
was changed to continuous daily dosing. Doses ranged from
1 mg qd to >20 mg bid. The pharmacokinetics of PD
0325901 and its metabolite PD 0315209 were assessed on
Day 1 (Cycles 1 and 2) and on Day 21. The effect of food on
the pharmacokinetics of PD 0325901 was evaluated in a
limited number of patients (Day 1 of Cycles 1 and 2).
Pharmacodynamic markers of MEK1/2 activity (pERK) and
cell proliferation (Ki67) were assessed by quantitative
immunohistochemistry in tumor biopsies obtained at baseline
and on Day 15 (2–4 h after dosing) [32,33].
After confirming the safety from once daily dosing, dose
escalation continued with bid dosing at 1, 2, 4, 8, 15, 20, and
30 mg and eventually switched to continuous dosing. From 35
evaluable patients, the most common adverse effects (observed
from ≥10% of patients) were rash (49%), diarrhea (49%),
fatigue (34%), visual disturbance (34%), nausea (29%), edema
(29%), pruritis (14%), anemia (11%) and dyspepsia (11%).
Dose-limiting toxicities were grade 3 rash in three patients,
cardiac adverse events presenting as congestive heart failure and
syncope in two patients, and a combination of anemia, diarrhea,
and mucositis in one patient. A neurologic adverse effect
presenting as transient cognitive impairment (confusion,
hallucination) was observed in 3 patients. CT and/or MRI
scans of the brain were negative and symptoms and signs
resolved after discontinuation of the MEK inhibitor therapy.
Onset of rash occurred within 1–2 weeks at all dose levels. The
frequency of and, to a lesser extent, the severity of rash generally
increased with the dose of PD 0325901. The severity of rash
often decreased during the one week dosing holiday, and
minocycline administered once or twice daily at 50 mg was
generally an effective treatment. Following unsuccessful treat-
ment with minocycline, 1 patient responded to prednisone
administered at a dose of 10 mg bid. There were no drug-related
adverse events of Grade 4 severity. At the time of reporting,dose-finding was ongoing to identify a recommended phase II
dose and schedule.
Nineteen of 35 patients had tumor tissues available for
evaluation of pERK inhibition. Phosphorylated ERK suppres-
sion was demonstrated at all dose levels and in all tumor types,
including melanoma, breast, colon, and lung. Preliminary
anticancer activity has also been evaluated from 27 assessable
patients. Two partial responses were observed in melanoma
patients, while 8 patients (5 melanoma, 2 NSCLC and 1 colon
cancer) achieved stable disease lasting 3–7 months (Unpub-
lished data).
3.4. ARRY-142886 (AZD6244)
ARRY-142886 (AZD6244), another novel and highly-
selective oral MEK inhibitor, is currently under study in clinical
trials. ARRY-142886 is a benzimidazole with reported nano-
molar activity against the purified MEK1 enzyme (Fig. 2) [34].
It is non-competitive with respect to ATP and is highly selective
for MEK1/2 compared to a panel of other tyrosine and serine/
threonine protein kinases [34]. In cell-based assays, MEK1/2,
which is measured by ERK1/2 phosphorylation levels, is
inhibited with an IC50 value of ∼10 nM [34–36]. Antiproli-
ferative effects of ARRY-142886 have been observed in cell
lines harboring Ras and B-Raf mutations [36]. It has also
demonstrated potent activity in a variety of human tumor
xenograft models, including colon, pancreas, breast, non-small-
cell lung carcinomas, and melanoma [37].
A first-in-human dose-ranging study (Part A) of ARRY-
142886 (AZD6244) was reported by Chow et al. at the AACR-
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and Cancer Therapeutics in November 2005 [38]. Twenty-three
patients with advanced solid malignancies were enrolled in this
trial. Doses of 50, 100, 200, and 300 mg BID were tested. The
most common treatment-related toxicities were rash (74%),
diarrhea (48%), nausea (39%), fatigue (30%), peripheral edema
(26%), vomiting (21%), change in taste (17%), and blurred
vision (17%). Grade 3 rash with or without grade 3 diarrhea
were the dose-limiting toxicities observed in 2 patients in the
300 mg BID cohort. The 200 mg bid cohort was expanded to a
total of 7 patients; only one DLT, presenting as grade 3 hypoxia,
was observed in this group. Therefore, 200 mg bid was
established as the MTD for ARRY-142886 (AZD6244).
Pharmacokinetics at the 200 mg BID administration of
ARRY-142886 showed a Cmax of 840 ng/ml and a Cmin of
390 ng/ml, with a half-life of 10.5 h. Phosphorylation of ERK
was also used as a pharmacodynamic biomarker in this study.
PBMCs isolated from patients were stimulated ex vivo, stained
for pERK and analyzed by flow cytometry. The inhibition of
TPA-induced pERK was well correlated to the plasma level of
ARRY-142886, with 50% inhibition observed at about 200 ng/
ml. Based on the pharmacokinetics, along with this pharmaco-
dynamic response, one can draw the conclusion that MEK
activity can be inhibited by more than 50% over a 24-h period in
patients and that this inhibition is tolerated.
Following the escalation phase (Part A), the Phase 1 trial
was expanded to further explore the safety and tolerability of
AZD6244 at the established MTD of 200 mg and one
additional dose of 100 mg (Part B). This expansion phase was
enriched to include 50% melanoma patients and 50% patients
with other advanced cancers, with paired biopsies taken pre-
dose and during treatment. This expansion phase has
completed enrollment and the results of this study were
reported at the EORTC-NCI-AACR Symposium on “Mole-
cular Targets and Cancer Therapeutics” in November 2006
[39]. Overall, 39 of 57 patients completed at least one cycle of
treatment with AZD6244. After completion of the second
cycle, 19 (49%) had stable disease, and nine of these patients
(six melanoma, one each of breast cancer, non-small cell lung
cancer and medullary thyroid cancer) remained stable for five
or more months (range, 5–14 months; median, 6 months). Two
patients, one with thyroid cancer and the other with melanoma,
continue to receive treatment with AZD6244 after one year.
Sixteen of the 20 patients with melanoma completed at least
one cycle of treatment. Twelve had stable disease after
completion of cycle two, with stable disease persisting for at
least five months in six patients (range, 5–13 months; median,
6.5 months). A phase II study that will compare AZD6244 to
temozolomide in the treatment of stage III / IV melanoma
commenced in June 2006. This study is an international multi-
center, randomized study that is designed to recruit approxi-
mately 180 patients.
4. Differential responses of MEK inhibition
The clinical development of MEK inhibitors appears to be on
a promising course. From the review of available safety data for135 phase I patients and 67 phase II patients, MEK inhibition
therapy appears to be well tolerated. Clinical benefit as
measured by objective responses has been limited, but in fact
appears much more promising if stable disease is used as an
indication of overall clinical benefit among this heavily
pretreated group of patients. From three published phase I and
phase II reports, stable disease was observed in 12%, 17% and
28% of treated patients, respectively [30–32].
It has been reported previously that much information can be
obtained from the examination of pERK in PBMCs; this is
because PBMCs can be obtained at multiple time points after
drug dosing and can be examined in patients at multiple doses,
which allows investigators to obtain pERK data at different
drug concentrations [38]. This allows for a thorough under-
standing of the dose–response relationship for inhibition of the
target in the blood compartment. In contrast, data on inhibition
of pERK in tumors is more difficult to obtain. Tissue samples
are often obtained at only one or two doses, at one time point
after a dose (typically Cmax) for comparison to a pre-dose level,
and can suffer more from sample variation, especially if
obtained by a fine needle biopsy. Typically, these data are
viewed as confirmatory of the results from the blood
compartment, to assess the accuracy of the PBMC data as a
surrogate. For example, data on ARRY-142886 was reported at
the EORTC meeting in Nov 2006, showing that tumor pERK
showed a mean inhibition of 84% compared to pre-dose levels
in patients receiving 100 mg BID [39]. This result confirmed
that the inhibition of pERK seen in PBMCs at that dose and
time translated well into an effect within the tumor. Thus,
PBMCs represent an essential surrogate for MEK inhibition
within the tumor. Though a mild association is seen between
baseline pERK levels in archived tumor samples and sub-
sequent stable disease in those patients treated with a MEK
inhibitor, pERK inhibition in either PBMCs or in tumor tissues
from patients receiving MEK inhibitor therapy has not
correlated with clinical benefit. Therefore, the presence of
activated ERK, as well as the percentage of ERK inhibition,
may not be sufficient in themselves as a guide to the anticancer
effects of MEK inhibition.
Based on available pre-clinical and clinical data, we have
speculated on a few possible factors that may influence the
potential therapeutic outcomes of MEK inhibition in cancer
patients: (1) The tumor pERK levels are examined at the
specified time points, and these data may reflect ERK activation
at that time, but may not differentiate between short-lived
mitogen-activation and sustained constitutive MAPK pathway
activation. Thus, the extent of MEK and pERK inhibition
observed in any one patient may or may not predict the ultimate
therapeutic response. It is possible that a more accurate
assessment of MEK inhibition may be obtained from an
examination of pERK inhibition from tumor biopsies performed
after reaching a steady-state drug level. A technical limitation
lies within tumor sampling itself; tumor heterogeneity is likely
to represent a key challenge in the attempt to quantitate the true
ERK activation status of a given tumor. Unless biopsies are
obtained from several different regions of a tumor, a true
representation of the tumor profile may not be obtained,
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have entered into clinical trials are non-competitive MEK
inhibitors with respect to ATP. This non-competitive character-
istic may, in part, contribute to the agent's potency in cells, due
to the fact that they are not affected by the high intracellular
ATP concentration. Alternatively, Ohren et al. demonstrated
that the high potency of MEK inhibitors, such as CI-1040, is
due to their very high affinity for a unique binding pocket
adjacent to the ATP-binding site that induces a conformational
change which locks unphosphorylated MEK into a closed,
catalytically inactive form [40]. Thus, they may have efficacy at
lower exposures in vivo. In addition, their action at an allosteric
site makes these molecules extremely selective for MEK versus
other kinases. Because of this selectivity it will be interesting to
see if these molecules turn out to be better tolerated than other,
ATP-competitive kinase inhibitors. (3) Constitutive activation
of the MAPK pathway can frequently lead to crosstalk with
other signal transduction pathways, which may provide
mechanisms of escape for cancer cells from MEK inhibition.
For example, the connection between the MAPK and
phosphatidylinositol 3-kinase (PI3K) pathway is a significant
factor; RAS serves as a primary effector for both RAF and PI3K
and thus activated MAPK signaling logically goes hand in hand
with increased flux through the PI3K pathway as reflected by
concurrent increases in phosphorylated AKT levels [41]. Recent
evidence from Smalley et al. showed that multiple signaling
pathways may need to be targeted for maximal therapeutic
efficiency [42]. Therefore, in certain genetic contexts, MEK
inhibitors might need to be used in combination with other
targeted therapies in order to maximize their effectiveness.
Inhibition of multiple signal transduction pathways may
synergize the anticancer activity of each individual small
molecule inhibitor. However, multi-signal pathway blockades
may generate intolerable side effects that limit or attenuate any
therapeutic benefits arising from such a combination. (4) Our
understanding of the biology of the response to MEK inhibitors
is incomplete. Clearly BRAF mutations can activate the
pathway, but not all cell lines with BRAF mutations are
sensitive to MEK inhibitors. Some cells with normal RAF,
especially those with N-Ras mutations, are also sensitive to
MEK inhibitors, but again this is not a universal rule. We need
to understand more about the roles of other mutations, such as
p-53, in cancer cells and of the apoptotic machinery in general,
and their roles in determining the apoptotic responses to MEK
inhibitors. (5) There is growing evidence in the clinic that
patients treated with kinase inhibitors can develop mutations
that can infer resistance. The best examples are the T315I
mutations in BCR-ABL in patients treated with imatinib [43]
and the T790M mutations in EGFR that confer resistance to
gefitinib and erlotinib [44]. Preclinically, mutant screening from
a MEK cDNA yeast library revealed several amino acids that,
when mutated, either hindered or completely abolished PD
184352-mediated inhibition of MEK kinase activity [45].
Recently, the first identified instance of naturally occurring
mutations in MEK1 and MEK2 were reported, in patients with
cardio-facio-cutaneous (CFC) syndrome [46]. The discovery
that germline mutations in MEK are associated with a specificdevelopmental syndrome may lead to even more importance
being placed on the development of MEK inhibitor therapy.
5. Future directions
As researchers continue to study the use of MEK inhibitors
in clinical trials, several questions remain unanswered. Fore-
most among them are these: What will be the clinical utility of
MEK inhibitors, and in what cancer patients, and with what
regimens and co-therapies?
As to which cancer patients to target, one possibility is that
the analysis of archival or fresh tumor may disclose a
correlation between patient response and genetic and/or
biochemical aberrations. As mentioned above, the target that
will receive the most attention initially is mutated BRAF.
Identification of relevant biomarkers may allow the pre-
selection of patient populations most likely to derive the
greatest clinical benefit. While BRAF mutations remain an
intriguing possibility, the current information has not allowed us
to draw any conclusions at this time.
In addition to genetic markers, it will be important to focus
efforts on the development of other early markers of response.
However, while the identification of early markers of response
will be helpful, it must be remembered that the most measurable
responses are tumor stabilization and/or shrinkage. At this time,
biomarkers/predictive markers appear too premature to be the
hinge that drives therapeutic programs utilizing MEK inhibitors
forward.
Once safety of these agents has been confirmed in humans,
we must design rational combination regimens with agents that
inhibit other targets in order to maximize response and prevent
resistance. Rational combinations need to take into account
many factors, among which are the activation of other pathways
that could compensate for inhibition of MEK, the effects of
MEK inhibitors on cell cycle, and the high proportion of
patients with stable disease. Indeed, long-term trials will need to
be done to understand the relationship between stable disease
with these compounds and any resulting increases in survival of
the patients.
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